4 Midcap Seven Year Stocks to Watch for Future Multibagger Potential: Uno Minda, Radico Khaitan, Ajanta Pharma and KPR Mill

Seven year stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Uno Minda, Radico Khaitan, Ajanta Pharma and KPR Mill meet that test, with market caps from Rs 35,061 crore to Rs 63,353 crore and Uno Minda offering the fastest profit growth, 38.65% a year since FY22. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a five-year return of at least 100 per cent and a return on equity of at least 15 per cent, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a five-year return of at least 100 per cent and a return on equity of at least 15 per cent, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening seven year stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 23 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Seven Year Stocks and Why Do They Attract Multibagger Interest?

Seven year stocks are shares of mid sized companies that have already doubled investors' money over five years while earning strong returns, a solid base for a seven-year holding. The four here cover auto components, spirits, pharmaceuticals and textiles.

A seven-year horizon covers a full business cycle, which lets strong earnings do the heavy lifting. For seven year stocks, both FY26 and the latest quarter showed growth. A sensible way to study seven year stocks is to look at profit growth, returns and valuation side by side. Below, each of seven year stocks gets its own breakdown of growth, returns and valuation. Treat seven year stocks as a research list, since share prices and rankings change with every earnings season.

Seven Year Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 23 October 2026. Ajanta Pharma combines the lowest PE of the group, 36.42, with the highest return on equity, 23.33%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Uno Minda	1,057	63,353	49.08	37.22	17.53%	0.40	994.00 to 1,355.00
Radico Khaitan	4,157.30	58,439	83.06	54.95	18.23%	0.15	2,500.00 to 4,747.00
Ajanta Pharma	3,283.90	41,336	36.42	36.35	23.33%	0.06	2,380.20 to 3,796.00
KPR Mill	1,024.60	35,061	38.43	36.46	15.21%	0.10	796.10 to 1,334.00

Uno Minda: 38.65% Profit CAGR Since FY22

Uno Minda makes switches, lighting, sensors and safety components for two-wheeler, passenger and commercial vehicle makers. It reported FY26 revenue of Rs 19,692.02 crore, up 17.19% year on year, and net profit of Rs 1,284.06 crore, up 25.82%. Net profit has compounded at 38.65% a year since FY22, while revenue has grown 23.83% a year. Operating margin was 12.75% in FY26. The debt-to-equity ratio is 0.40.

In the June 2026 quarter, revenue rose 23.60% to Rs 5,563.16 crore and net profit grew 2.10% to Rs 315.51 crore. The share price has gained 187.71% over five years. Domestic institutions raised their holding from 15.85% in June 2025 to 17.53% in June 2026. The stock trades at a PE of 49.08 against an industry PE of 37.22, with a return on equity of 17.53%.

Radico Khaitan: 24.88% Profit CAGR Since FY22

Radico Khaitan makes Indian-made foreign liquor and premium spirits, with brands including Magic Moments, 8PM and Rampur Single Malt. It reported FY26 revenue of Rs 6,062.27 crore, up 24.84% year on year, and net profit of Rs 604.48 crore, up 74.90%. Net profit has compounded at 24.88% a year since FY22, while revenue has grown 20.50% a year. Operating margin was 4.88% in FY26. The debt-to-equity ratio is 0.15, which keeps interest costs low.

The stock trades at a PE of 83.06 against an industry PE of 54.95, with a return on equity of 18.23%. In the June 2026 quarter, revenue rose 10.44% to Rs 5,869.46 crore and net profit grew 75.91% to Rs 229.60 crore. The share price has gained 299.58% over five years and 51.47% over the past year. Domestic institutions raised their holding from 25.47% in September 2025 to 27.17% in September 2026.

Ajanta Pharma: Return on Equity of 23.33%

Ajanta Pharma sells branded generics in ophthalmology, dermatology, cardiology and pain management in India, Africa and Asia. It reported FY26 revenue of Rs 5,624.93 crore, up 18.60% year on year, and net profit of Rs 1,056 crore, up 14.73%. Net profit has compounded at 10.33% a year since FY22, while revenue has grown 12.94% a year. Operating margin was 28.74% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

In the June 2026 quarter, revenue rose 27.68% to Rs 1,696.86 crore and net profit grew 30.89% to Rs 334.22 crore. The share price has gained 125.31% over five years and 35.42% over the past year. Domestic institutions raised their holding from 17.90% in September 2025 to 21.94% in September 2026. The stock trades at a PE of 36.42 against an industry PE of 36.35, with a return on equity of 23.33%.

KPR Mill: Debt-to-Equity of 0.10

KPR Mill is an integrated textile maker that produces yarn, knitted fabric and garments and also runs a sugar and ethanol business. It reported FY26 revenue of Rs 6,784.29 crore, up 4.98% year on year, and net profit of Rs 866.50 crore, up 6.30%. Revenue has compounded at 8.42% a year since FY22. Operating margin was 21.07% in FY26. The debt-to-equity ratio is 0.10, which keeps interest costs low.

The stock trades at a PE of 38.43 against an industry PE of 36.46, with a return on equity of 15.21%. In the June 2026 quarter, revenue rose 9.32% to Rs 1,970.26 crore and net profit grew 21.55% to Rs 258.54 crore. The share price has gained 130.83% over five years. Foreign investors raised their holding from 6.45% in September 2025 to 7.01% in September 2026.

Seven Year Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these seven year stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	4-Year Net Profit CAGR	Operating Margin (Latest Quarter)
Uno Minda	19,692.02	1,284.06	17.19%	23.83%	38.65%	11.26%
Radico Khaitan	6,062.27	604.48	24.84%	20.50%	24.88%	6.10%
Ajanta Pharma	5,624.93	1,056	18.60%	12.94%	10.33%	30.41%
KPR Mill	6,784.29	866.50	4.98%	8.42%	0.72%	22.09%

Check the Univest Screener for live data on these seven year stocks

Institutional Holding in Uno Minda, Radico Khaitan, Ajanta Pharma and KPR Mill

Institutional holding shows who is backing these seven year stocks alongside the promoter. The table uses the latest reported quarter for each. Radico Khaitan has the deepest institutional backing, with FII and DII together holding 46.60% as of September 2026. Domestic institutions increased their holding over the past year in Uno Minda (from 15.85% to 17.53%), Radico Khaitan (from 25.47% to 27.17%) and Ajanta Pharma (from 17.90% to 21.94%).

Stock	Promoter	FII	DII	Public	Quarter
Uno Minda	68.36%	8.15%	17.53%	5.96%	June 2026
Radico Khaitan	40.17%	19.43%	27.17%	13.23%	September 2026
Ajanta Pharma	63.47%	7.63%	21.94%	6.96%	September 2026
KPR Mill	67.52%	7.01%	19.15%	6.31%	September 2026

Risks to Weigh in Seven Year Stocks

Being careful with seven year stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Radico Khaitan trades at a PE of 83.06 against an industry PE of 54.95, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Seven Year Stocks

Picking from seven year stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (36.35 to 54.95) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Uno Minda, Radico Khaitan, Ajanta Pharma and KPR Mill live prices.

Conclusion

Among seven year stocks, Uno Minda stands out for the fastest profit growth, 38.65% a year since FY22, Radico Khaitan for the biggest five-year price gain at 299.58%, Ajanta Pharma for the highest return on equity at 23.33% and KPR Mill for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.10. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing seven year stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Seven Year Stocks to Watch

Which are the best seven year stocks to watch for multibagger potential?

Ans. Uno Minda, Radico Khaitan, Ajanta Pharma and KPR Mill are the 4 names this list highlights, with market caps of Rs 63,353 crore, Rs 58,439 crore, Rs 41,336 crore and Rs 35,061 crore respectively. Uno Minda is notable for the fastest profit growth, 38.65% a year since FY22. Radico Khaitan stands out for the biggest five-year price gain at 299.58%. Ajanta Pharma offers the highest return on equity at 23.33%. KPR Mill brings a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.10. These are watchlist names for seven year stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Ajanta Pharma a good stock for long-term investors?

Ans. Ajanta Pharma has a return on equity of 23.33%, a PE of 36.42 against an industry PE of 36.35 and a market cap of Rs 41,336 crore. Net profit has compounded at 10.33% a year since FY22, and FY26 revenue rose 18.60% while June 2026 quarter net profit grew 30.89%. Long-term returns in seven year stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Uno Minda become a multibagger from here?

Ans. Uno Minda has already gained 187.71% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in seven year stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 38.65% a year since FY22, and FY26 revenue rose 17.19%. At a PE of 49.08 against an industry PE of 37.22, valuation should be checked against that growth before investing.

What is the market cap of Uno Minda, Radico Khaitan, Ajanta Pharma and KPR Mill?

Ans. As of 23 October 2026, Uno Minda has a market cap of Rs 63,353 crore, Radico Khaitan has a market cap of Rs 58,439 crore, Ajanta Pharma has a market cap of Rs 41,336 crore and KPR Mill has a market cap of Rs 35,061 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on seven year stocks.

What are the risks of investing in seven year stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Radico Khaitan trades at a PE of 83.06 against an industry PE of 54.95, so earnings growth needs to hold up.

Why is Radico Khaitan trading at a PE of 83.06?

Ans. Radico Khaitan's PE of 83.06 compares with an industry PE of 54.95. The market is paying a premium for a return on equity of 18.23%, profit growth of 24.88% a year since FY22 and latest-quarter profit growth of 75.91%, which also means the stock is more sensitive if growth slows. Investors in seven year stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Uno Minda, Radico Khaitan, Ajanta Pharma and KPR Mill?

Ans. As of the latest reported quarter, FII and DII together hold 25.68% of Uno Minda (8.15% and 17.53%), 46.60% of Radico Khaitan (19.43% and 27.17%), 29.57% of Ajanta Pharma (7.63% and 21.94%) and 26.16% of KPR Mill (7.01% and 19.15%). Rising institutional holding is a useful signal in seven year stocks, though it should be read with earnings trends rather than on its own.